SPAC631.02 Antibody

What is SPAC631.02 and why is it important for antibody research?

SPAC631.02 encodes a 769-amino-acid protein in Schizosaccharomyces pombe (fission yeast) that contains two bromodomains (the double bromodomain). This protein is closely related to S. cerevisiae Bdf1 and Bdf2, which are known to be involved in gene regulation . The double bromodomain structure is significant because it recognizes acetylated lysine residues on histones, making it important for chromatin-mediated processes.

Antibodies against SPAC631.02 (also referred to as bdf2) are valuable tools for studying:

• Chromatin regulation mechanisms

• DNA replication and checkpoint responses

• Gene expression control in fission yeast

• Protein-protein interactions with other regulatory factors

How can researchers validate the specificity of SPAC631.02 antibodies?

Validating antibody specificity for SPAC631.02 requires a multi-faceted approach:

Recommended validation methods:

• Genetic validation: Testing antibody reactivity in wild-type versus Δbdf2 (SPAC631.02 deletion) strains, as demonstrated in checkpoint mutant studies

• Western blot analysis: Confirming single band of expected molecular weight (~85 kDa)

• Immunoprecipitation followed by mass spectrometry: Similar to methods used for SpA5 antibody validation , confirming specific target pull-down

• Epitope competition assays: Using recombinant SPAC631.02 protein to compete for antibody binding

For highest confidence, implement standardized consensus antibody characterization protocols as described in recent literature for other research antibodies .

What controls should be included when using SPAC631.02 antibodies?

How can SPAC631.02 antibodies be optimized for Western blotting experiments?

For optimal Western blot results with SPAC631.02 antibodies:

• Sample preparation:

  • Extract proteins using FA lysis buffer (50 mM HEPES-KOH, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.2% SDS, 0.1% Na-deoxycholate, 1 mM PMSF)

  • For bromodomain proteins, include deacetylase inhibitors (e.g., sodium butyrate, TSA) to preserve acetylation states

• Gel electrophoresis conditions:

  • Use 8% SDS-PAGE gels to effectively resolve the ~85 kDa protein

  • Both reducing and non-reducing conditions may be tested, similar to protocols for other antibodies

• Transfer and detection:

  • Transfer to PVDF membrane at 100V for 90 minutes in 10% methanol buffer

  • Block with 5% non-fat milk or BSA in TBST

  • Primary antibody dilution: Start at 1:1000 and optimize as needed

  • Detection using HRP-conjugated secondary antibodies and enhanced chemiluminescence

• Troubleshooting:

  • If multiple bands appear, increase washing stringency or adjust antibody concentration

  • For weak signals, increase protein loading or extend primary antibody incubation time

What is the recommended protocol for using SPAC631.02 antibodies in chromatin immunoprecipitation (ChIP) assays?

Based on established ChIP protocols for S. pombe bromodomain proteins :

• Cross-linking and cell lysis:

  • Fix asynchronously or synchronously cultured cells with 3% formaldehyde on ice for 30 minutes

  • Quench with 330 mM glycine on ice for 10 minutes

  • Wash with ice-cold 1× PBS

  • Resuspend in FA lysis buffer (50 mM HEPES-KOH, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.2% SDS, 0.1% Na-deoxycholate, 1 mM PMSF with protease inhibitors)

  • Break cells by vortexing with glass beads

  • Clear lysates by centrifugation at 12,000 ×g

• Immunoprecipitation:

  • Pre-clear chromatin with protein A/G beads

  • Incubate with SPAC631.02 antibody overnight at 4°C (typically 2-5 μg per sample)

  • Add protein A/G beads and incubate for 2-3 hours

  • Wash extensively with increasingly stringent buffers

• DNA recovery and analysis:

  • Reverse cross-links at 65°C overnight

  • Treat with proteinase K and RNase A

  • Purify DNA using phenol-chloroform extraction or commercial kits

  • Analyze by qPCR or sequencing

• Key targets to examine:

  • AACCCT-box containing promoters, as Ams2 (which interacts with this region) binds to the upstream region of SPAC631.02

  • Genes involved in checkpoint response, based on genetic interaction data

How can researchers use SPAC631.02 antibodies to study protein-protein interactions?

For studying interactions between SPAC631.02 and other proteins (e.g., Ams2 ):

• Co-immunoprecipitation:

  • Prepare cell lysates under non-denaturing conditions

  • Immunoprecipitate with SPAC631.02 antibody

  • Analyze co-precipitated proteins by Western blot with antibodies against suspected interaction partners

  • Confirm specificity using deletion mutants as controls

• Proximity ligation assay (PLA):

  • Fix and permeabilize cells

  • Incubate with primary antibodies against SPAC631.02 and potential interaction partner

  • Use secondary antibodies conjugated with PLA probes

  • Perform ligation and amplification reactions

  • Visualize interaction signals by fluorescence microscopy

• Size-exclusion chromatography followed by Western blot:

  • Apply native cell extracts to a size-exclusion column

  • Collect fractions and analyze by Western blot using SPAC631.02 antibody

  • Compare migration patterns with potential interaction partners

  • Similar to the approach used to study Clr6-13MYC and Fkh2-TAP interactions

How can SPAC631.02 antibodies help elucidate the role of this protein in checkpoint response?

Genetic studies show that deletion of SPAC631.02 (bdf2) partially rescues hydroxyurea (HU) sensitivity of swi1Δ cells, suggesting a role in the checkpoint response pathway . Antibodies can be used to:

• Monitor protein levels during checkpoint activation:

  • Synchronize cells using centrifugal elutriation or temperature-sensitive cdc25-22 mutants

  • Treat with HU to induce checkpoint activation

  • Collect time-course samples and analyze SPAC631.02 protein levels by Western blot

  • Compare with checkpoint proteins like Cds1 to determine temporal relationships

• Analyze chromatin association dynamics:

  • Perform ChIP-seq before and after HU treatment

  • Identify genomic regions where SPAC631.02 binding changes during checkpoint activation

  • Correlate with histone acetylation marks and transcriptional changes

• Identify post-translational modifications:

  • Immunoprecipitate SPAC631.02 from normal and checkpoint-activated cells

  • Analyze by mass spectrometry to identify differentially modified residues

  • Validate functional significance using phospho-specific or acetyl-specific antibodies

What techniques can be used to study the functional relationship between SPAC631.02 and chromatin regulation?

As a double bromodomain protein related to S. cerevisiae Bdf1/2, SPAC631.02 likely plays a role in chromatin regulation:

• Sequential ChIP (ChIP-reChIP) analysis:

  • Perform first ChIP with SPAC631.02 antibody

  • Elute complexes and perform second ChIP with antibodies against histone marks

  • Analyze co-occupancy at specific genomic loci

• CRISPR-mediated tagging combined with antibody detection:

  • Tag endogenous SPAC631.02 with a small epitope (e.g., FLAG)

  • Perform ChIP-seq with both tag-specific and SPAC631.02-specific antibodies

  • Compare binding profiles to validate antibody specificity and identify binding sites

• Histone peptide binding assays:

  • Prepare arrays of modified histone peptides

  • Incubate with recombinant SPAC631.02 protein

  • Detect binding using SPAC631.02 antibodies

  • Identify specific histone modifications recognized by the bromodomains

How can researchers address potential cross-reactivity with related bromodomain proteins?

Cross-reactivity is a critical concern given the presence of another double bromodomain protein in S. pombe (Bdf1, encoded by SPCC1450.02) :

• Epitope mapping and selection:

  • Identify unique regions of SPAC631.02 not conserved in Bdf1

  • Generate antibodies against these unique epitopes

  • Validate using recombinant proteins and genetic knockouts

• Immunodepletion strategy:

  • Pre-incubate antibody with recombinant Bdf1 protein to absorb cross-reactive antibodies

  • Use the depleted antibody preparation for experiments

  • Confirm specificity using Western blot against both proteins

• Quantitative analysis of antibody specificity:

  • Express and purify recombinant SPAC631.02 and Bdf1

  • Perform quantitative ELISAs to determine relative binding affinities

  • Calculate cross-reactivity percentages similar to methods used for other antibodies

How should researchers interpret conflicting results between antibody-based detection and genetic approaches?

When discrepancies arise between antibody-based studies and genetic results:

• Verify antibody specificity:

  • Repeat validation using multiple methods (Western blot, IP-MS, genetic knockouts)

  • Test different antibody lots and sources if available

  • Consider epitope masking due to protein interactions or modifications

• Examine experimental conditions:

  • Different growth conditions may affect protein expression or localization

  • Cell synchronization methods can impact protein levels and modifications

  • Extraction methods may differentially recover protein populations

• Consider protein dynamics:

  • Transient interactions may be captured by antibodies but missed in steady-state genetic analyses

  • Post-translational modifications might affect antibody recognition but not genetic function

  • Compensatory mechanisms may mask phenotypes in genetic knockouts

• Reconciliation approaches:

  • Use orthogonal methods (e.g., tagged versions of the protein)

  • Perform time-course experiments to capture dynamic changes

  • Combine genetic and antibody approaches (e.g., ChIP in mutant backgrounds)

What are the most common technical issues when using SPAC631.02 antibodies?

How can active learning approaches improve experimental design when working with SPAC631.02 antibodies?

Active learning strategies can significantly improve experimental efficiency when characterizing and using SPAC631.02 antibodies:

• Sequential experimental design:

  • Start with small-scale pilot experiments to optimize conditions

  • Use results to inform subsequent larger-scale studies

  • Implement iterative learning similar to antibody-antigen binding prediction studies

• Multi-parameter optimization:

  • Systematically vary antibody concentration, incubation time, and buffer conditions

  • Use factorial design to identify optimal combinations

  • Develop standardized protocols for consistent results

• Machine learning integration:

  • Apply algorithms to predict optimal experimental conditions based on protein properties

  • Use data from related bromodomain antibodies to inform experimental design

  • Implement active learning strategies that have been shown to reduce required experimental variants by up to 35%

• Cross-validation approaches:

  • Implement orthogonal validation methods similar to those used for clinical antibodies

  • Design competition binding assays to assess epitope specificity

  • Develop standardized quality control metrics for consistent antibody performance